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Treatment  of  AIDS  (HIV)  and  hepatitis  C  virus  needs 
protease inhibitors (PI) to prevent viral replication. Uses 
of PI in therapy are usually associated with a decrease in 
body  weight  and  dyslipidemia.  Acylation  stimulating 
protein  (ASP)  is  a  protein  synthesized  in  adipocytes  to 
increase triglycerides biosynthesis, for that the relation of 
PI and ASP to adipogenesis is tested in this work. ASP 
expression  was  increased  during  3T3-L1  differentiation 
and  reached  a  peak  at  day  8  with  cell  maturation. 
Addition  of  PI  during  adipocytes  differentiation  dose 
dependently  and  significantly  (p  ＜  0.5)  inhibited  the 
degree  of  triglycerides  (TG)  accumulation.  Moreover, 
presence of ASP (450 ng/mL) in media significantly (p ＜ 
0.5) stimulated the degree of TG accumulation and there 
was additive stimulation for ASP when added with insulin 
(10  μg/mL). Finally, when ASP in different doses (Low, 
16.7; Medium, 45 and High, 450 ng/mL) incubated with a 
dose of ×150 PI, ASP partially inhibited the PI-inhibited 
adipogenesis  and  TG  accumulation.  The  results  in  this 
study  show  that  PI  inhibit  lipids  accumulation  and 
confirm role of ASP in TG biosynthesis and adipogenesis.
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Introduction 
Protease inhibitors (PI) are a class of medications used to 
treat viral infections such as HIV (AIDS) and hepatitis C 
virus [2]. PI prevents viral replication by inhibiting the 
activity of protease, an enzyme used by the viruses to 
cleave nascent proteins for final assembly of new virons 
[2]. PI is a cocktail of water-soluble protease inhibitors 
with a broad specificity for the inhibition of serine, 
cysteine, and metalloproteases. It has been known that 
protease inhibitors act as antiretroviral, antiprotozoal and 
anticancer activity and they include 1) aminoethyle 
benzenesulfonyl fluoride and aprotonin which inhibit 
which trypsin, chymotrypsin, plasmin and thrombin, 2) 
EDTA- metalloproteases, 3) leupeptin hemisulfate salt as 
plasmin and cathepsin, 4) cystein proteases as leucin 
aminopeptidase and alanyl aminopeptidase.
The use of retroviral PI in conjunction with other 
antiretroviral drugs, has dramatically improved the 
morbidity and mortality associated with HIV infection 
[22]. However, patients under antiretroviral therapy 
develop a lipodystrophic syndrome as shown by altered 
body fat distribution and alterations of glucose and lipid 
metabolism [3,4,17,22]. In the blood, serum triglycerides 
and cholesterol are increased in these patients. There is also 
a high prevalence of hyperinsulinemia and insulin 
resistance, which results in diabetes [4,23]. It has been 
known that PI might inhibit adipocyte differentiation 
through the inhibition of peroxisome proliferators 
activated receptor gamma (PPARγ) and retonid X receptor 
that known to be a potent mediator of adipogenesis [1,21].
 As known, fat deposition depends on accumulation of 
triacylglycerides in adipocytes [12]. Adipose tissue can 
convert glucose and amino acids into fatty acids when 
stimulated by insulin [10,14]. Adipose tissue can also 
secrete hormones and cytokines for its own regulation 
[13]. Human fat cells have been shown to have mRNA for 
adipsin (complement factor D), 3rd complement component 
(C3) and factor B, all of which are components necessary 
to generate activated C3 (C3a), the precursor for acylation 
stimulating protein (ASP). It was initially identified from 
human plasma [7], and determined to be a derivative of the 
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results in C3a-desArg that is known as ASP [16].
Human and rodent adipocytes synthesis and secret 
complement factors such as C3, B and adipsin [5,8]. ASP 
acts on adipocyte membrane to increase glucose transport 
and diacylglycerol acyltransferase activity [11], so ASP 
influences tri-acyle-glycerol (TAG) biosynthesis in adipocytes 
[19]. Basal production of ASP in adipocytes is dependent 
on rate of adipocytes differentiation [6]. In addition, ASP 
stimulates glucose uptake through the translocation of 
glucose transporters Glut 1 and Glut 4 from the intracellular 
pool to the cell membrane [11]. Finally, similar to insulin, 
ASP inhibits hormone sensitive lipase (HSL) through 
stimulation of phosphodiesterase, thus inhibiting lipolysis 
in human adipocytes [20]. The relation between adipogenesis, 
PI and ASP is elucidated well. For that, we examined the 
effect of PI and ASP alone and in combination on 
adipocytes differentiation and triglycerides accumulation 
in 3T3-L1 cells. 
Materials and Methods
Materials
　Dulbecco’s modified Eagles medium (DMEM), bovine 
serum albumin, bovine insulin and isobutylmethylxanthine 
(IBMX) were purchased from Sigma-Aldrich (USA). Fetal 
calf serum (FCS) was from Trace Scientific (Australia), 
dexamethasone, antibiotics (penicillin and streptomycin) 
and troglitazone were purchased from Wako Pure Chemicals 
(Japan). Protease inhibitor cocktail was from Sigma- 
Aldrich, USA and 3T3-L1 cells were from Zen-Bio, USA.
3T3-L1 cells differentiation and methodology
3T3-L1 cells were grown in DMEM containing 10% FCS 
and antibiotics (100 U/mL penicillin, and 100 μg/mL 
streptomycin). When cells reached confluence (referred to 
day 0), the cells were cultured in DMEM contains 0.5 mM 
IBMX, 1 μM dexamethasone, and 10 μg/mL insulin for 2 
days, and subsequently in fresh DMEM containing 10% 
FCS, 10 μM troglitazone and 10 μg/mL insulin every 2 
days for 12 days to achieve cell differentiation to mature 
adipocytes. To test the effect of PI on lipids accumulation 
in adipocytes, PI was added from day 4 to day 8 in doses of 
×300, ×200, ×150 and ×100. To test the effect of PI and 
ASP, on day 4 of differentiation, the cells were incubated 
with insulin, PI alone or together for 4 days then stained 
with oil red O as shown down. To test the effect of ASP, on 
day 4 of differentiation, ASP in different doses different 
doses (Low, 16.7; Medium, 45 and High, 450 ng/mL) was 
added to insulin (10 μg/mL) alone or in combination with 
PI (×150) every day for 4 days and the cells were stained by 
oil red O.
RT-PCR analysis
Total RNA was extracted from culture adipocytes from 
day 0 (day of confluence) to day 12 of differentiation to test 
ASP expression.by the guanidine-isothiocyanate method 
using TRIzol reagent (Gibco, USA). RNA (1 μg) was 
treated at 72
oC for 5 min and reverse transcribed using 100 
units of Moloney murine leukemia virus reverse transcriptase 
(Gibco, USA), 50 pmol of poly (dT) primer and 20 nmol of 
dNTPs in a total volume of 10 μL at 37
oC for 1 h. After 
heating at 94
oC for 5 min, PCR amplification was performed 
with 2.5 units Taq polymerase (Perkin-Elmer, USA), 3 mM 
MgCl2 and 50 pmol of forward and reverse primers 
specific for respective genes in a total volume of 50 μL. 
The primer pairs and PCR condition of ASP and glyceraldehydes- 
3-phosphate dehydrogenase (G3PDH) were as following: 
for ASP the primer pairs and PCR condition forward, 
5´-GTCTTCACGGATGCAGGACTCA-3´ reverse, 5´-T 
CAATGACGGTCCACAACC-3´ the annealing temperature 
was 58
oC for 1 min to amplify a product of 460 bp. The 
reaction was carried out for 30 cycles. For bovine G3PDH, 
PCR condition was as follows, the annealing temperature 
was 59
oC for 30 sec, the forward primer: 5´-ACCACTGT 
CCACGCCATCAC-3´ and the reverse primer: 5´-TCC 
ACCACCCTGTTTGCTGTA-3´ the reaction was carried 
out for 25 cycles to amplify a product of 450 bp. After 
electrophoresis in 1.5% agarose gel, the PCR products 
were stained with ethidium bromide and visualized under 
UV lamp.
Oil red O staining
Cultured preadipocytes when reached confluence (day 0) 
and till 12 days of adipogenic differentiation were fixed 
with 10% formalin in isotonic phosphate buffer for 1 h, 
stained with 0.5% oil red O in 60% isopropyl alcohol for 1 
h and rinsed extensively with water, lipid droplets were 
stained red. After visualization under binuclear ordinary 
microscope (×400), oil red O stained lipid droplets were 
extracted by 1 mL of absolute isopropyl alcohol and 
quantified by measuring absorbance in spectrophotometer 
at 540 nm.
Statistical analysis
All data were expressed as means ± SE and analyzed by 
Dunnett’s t-test for multiple comparisons with a single 
control group using specific program (StatView Version-5; 
SAS Institute, Japan) for Macintosh computer. Significance 
was reported as p ＜ 0.05.
Results
As seen in Fig. 1, the ASP expression was examined up to 
12 days as seen it was time dependently increased using 
RT-PCR analysis. This increase in ASP expression was 
recorded in day 4 and reached the plateau at 8 days, and 
continued high up to 12 days. Next, the degree of lipids 
accumulation was examined microscopically in presence ASP inhibited PI inhibited adipogenesis in 3T3-L1 cells    199
Fig. 1. Time dependent increase in acylation stimulating 
protein (ASP) expression during differentiation of 3T3-L1 cells. 
Every 2 days, RNA was extracted up to 12 days and reverse 
transcribed and RT-PCR analysis was carried out. (A) RT-PCR 
analysis for ASP expression, upper bands for ASP and the lower 
is for glyceraldehydes-3-phosphate dehydrogenase (G3PDH). 
(B) Densitometric analysis (fold increase) of ASP bands relative 
to G3PDH (internal control).
Fig. 2. Effect of PI on adipogenesis in 3T3-L1 cells. Cells were 
incubated with insulin for 4 days and then with PI in different 
dose to observe lipids accumulation. (A) Control; Showing 
fibroblast like cells without lipids accumulation. (B) Insulin 
alone (10 μg/mL); Cells became round and a marked increase in
lipids was recorded. (C-F) C; Insulin plus PI (×300), D; Insulin 
plus PI (×200), E; Insulin plus PI (×150) and F; Insulin plus PI 
(×100). Oil red O stain, ×400.
Fig. 3. Inhibitory effect of PI on adipogenesis in 3T3-L1 cells. 
Lipids accumulation measured spectrophotometrically at OD 
540 nm. The lipids were removed from cells after staining by oil 
red O and removed by isopropanol. Values are means ± SE 
obtained from 3 experiments. *p ＜ 0.05 compared to control and 
†p ＜ 0.05 compared to insulin.
or absence of PI. The presence of insulin alone (10 μg/mL) 
increased the lipids accumulation. Addition of PI dose 
dependently inhibited adipogenesis and lipids accumulation 
(Fig. 2). When the degree of lipids accumulation measured 
specrophotometrically, the effect was clear and significantly 
(p ＜ 0.05) increased with insulin (2 fold increase) and 
inhibited when co-treated with different doses of PI in 
comparing with insulin and control (Fig. 3).
To test that effect, cells were incubated with insulin and as 
seen in Fig. 4, the level of adipocytes differentiation and 
lipids accumulation was increased. Moreover, when it 
incubated with ASP in high dose (450 ng/mL) together with 
insulin, there was an additive increase in lipids accumulation 
was seen (Fig. 4). When the cells were incubated in 
presence of insulin and PI, TG accumulation was decreased. 
When ASP in low, medium and high doses of ASP was 
added together with insulin and PI, TG accumulation was 
partially reversed when compared with that of insulin and 
PI together (Figs. 4 and 5).
Discussion
The results presented in this study showed that PI 
inhibited TG accumulation and inhibition was partially 
reversed by addition of ASP. This study focused on the role 
of ASP in adipogenesis alone and in combination with PI, 
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Fig. 4. Effect of PI on ASP stimulated lipids accumulation in 
3T3-L1 cells. Cells were incubated for 4 days with either insulin 
(10 μg/mL) or ASP in high dose (ASPH, 450 ng/mL) plus insulin
(10 μg/mL). Also, cells were incubated with PI (×150), insulin 
and different doses of ASP, ASP in low dose (ASPL; 16.7 ng/mL),
medium dose of ASP (ASPM; 45 ng/mL) and ASPH. (A) Control;
Showing fibroblast like cells without lipids accumulation. (B) 
Insulin alone; Cells became round and marked increase in lipids 
accumulation (C) Insulin plus ASPH; Showing more lipids 
accumulation. (D) Insulin plus PI (×150); Lipids accumulation 
was moderately decreased in the presence. (E-G) E; Insulin plus
PI (×150) and ASPL, F; Insulin plus PI (×150) and ASPM, G; 
Insulin plus PI (×150) and ASPH. Oil red O stain, ×400. 
Fig. 5. Effect of PI on ASP stimulated lipids accumulation in 
3T3-L1 cells. Mature cells were incubated for 4 days as described
in Fig. 4. Lipid accumulation was measured spectrophotmetrically
at OD 540 nm. The lipids were removed from cells after staining
by oil red O and removal by isopropanol. Values are means ± SE 
obtained from 3 experiments. *p ＜ 0.05 compared to control, †p
＜ 0.05 compared to insulin, ‡p ＜ 0.05 compared to insulin plus
PI and, §p ＜ 0.05 compared to insulin and insulin plus ASP.
hepatitis C and AIDS patients [2]. In this study, ASP 
expression was highly expressed during cell differentiation 
and maturation and confirmed the relation between ASP 
and TG accumulation; comparable finding was confirmed 
in another study in bovine adipose tissue explants [13].
Our data showed that ASP expression increased during 
differentiation of preadipocytes and same findings was 
reported in another study [15]. Furthermore, Koistinen et 
al. [15] reported that there was no increase in plasma ASP 
levels in response to an oral fat load. However, there was 
parallel correlation between the magnitude of postprandial 
lipemia and fasting ASP levels or subcutaneous adipose 
tissue C3 mRNA expression.
The exact mechanism of adipogenesis inhibition by PI is 
not well defined, but two pathways involved in that 
inhibition were confirmed, sterol regulatory element 
binding protein1 and PPARγ [2,19,21]. We can say that PI 
may inhibites ASP expression in mature adipocytes 
through modulation of other known genes that involved in 
TG biosynthesis as ASP and HSL [9,13]. In the study of De 
Barros et al. [9], the chronic lactacystin treatment of 
preadipocytes in an adipogenic medium led to a decrease 
of various differentiation markers such as triglyceride 
content, fatty acid binding protein-2 and HSL expression 
[9]. To our knowledge, this is the first investigation 
showing that PI cocktail has an inhibitory effect on 3T3-L1 
preadipocytes differentiation is partially inhibited in 
presence of ASP.
It is known that PPARγ agonist are potent stimulators of 
adipocytes differentiation, so it is possible that PI induced 
its effect by inhibition of PPARγ expression, but Zhang et 
al. [25] found that PI failed to stimulate transcriptional 
activation of PPARγ in mammalian cells. Therefore, PI 
used for treatment of HIV inhibitors, may act as indirect 
inhibitors that antagonize the expression of adipogenesis 
related genes [2]. Xia et al. [24] reported that ASP is an 
important factor in regulating metabolic balance. The 
absence of ASP production results in increased energy 
expenditure in mice through its effect on TG synthesis and 
decrease peripheral energy expenditure [24]. ASP signaling 
involves sequential activation of PI3K, with downstream ASP inhibited PI inhibited adipogenesis in 3T3-L1 cells    201
activation of protein kinase C, Akt and MAPK/ERK1/2, all 
of which lead to an effective and prolonged stimulation of 
TG synthesis [16]. In conclusion, this study showed the 
stimulatory effect of ASP and the inhibitory effect PI on 
adipogenesis in 3T3-L1 cells and that effect partially 
inhibited when cells co-treated with PI and ASP.
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